Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer.

Lin C, Bai S, Du T, Lai Y, Chen X, Peng S, Ma X, Wu W, Guo Z, Huang H.

Cancer Manag Res. 2019 Feb 14;11:1517-1524. doi: 10.2147/CMAR.S176762. eCollection 2019.

2.

Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.

Singh L, Pushker N, Sen S, Singh MK, Chauhan FA, Kashyap S.

Clin Exp Ophthalmol. 2015 Aug;43(6):550-7. doi: 10.1111/ceo.12517. Epub 2015 May 13.

PMID:
25754767
3.

Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.

Zhuo YJ, Liu ZZ, Wan S, Cai ZD, Xie JJ, Cai ZD, Song SD, Wan YP, Hua W, Zhong W, Wu CL.

Biomed Pharmacother. 2018 Jun;102:531-538. doi: 10.1016/j.biopha.2018.03.079. Epub 2018 Mar 26.

PMID:
29587239
4.

Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.

Peng S, Du T, Wu W, Chen X, Lai Y, Zhu D, Wang Q, Ma X, Lin C, Li Z, Guo Z, Huang H.

Urol Oncol. 2018 Aug;36(8):366.e1-366.e9. doi: 10.1016/j.urolonc.2018.05.021. Epub 2018 Jun 19.

PMID:
29903461
5.

Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma.

Juntermanns B, Sydor S, Kaiser GM, Jaradat D, Mertens JC, Sotiropoulos GC, Swoboda S, Neuhaus JP, Meng W, Mathé Z, Baba HA, Canbay A, Paul A, Fingas CD.

Liver Int. 2015 Nov;35(11):2448-57. doi: 10.1111/liv.12839. Epub 2015 Apr 10.

PMID:
25818805
6.

Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3.

Conn CW, Hennigan RF, Dai W, Sanchez Y, Stambrook PJ.

Cancer Res. 2000 Dec 15;60(24):6826-31.

7.

Effect of hypoxic stress-activated Polo-like kinase 3 on corneal epithelial wound healing.

Lu J, Wang L, Dai W, Lu L.

Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5034-40. doi: 10.1167/iovs.10-5501. Epub 2010 May 26.

8.

Polo-like kinases and oncogenesis.

Eckerdt F, Yuan J, Strebhardt K.

Oncogene. 2005 Jan 10;24(2):267-76. Review.

PMID:
15640842
9.

Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.

Wang H, Tian C, Fan XY, Chen LN, Lv Y, Sun J, Zhao YJ, Zhang LB, Wang J, Shi Q, Gao C, Chen C, Shao QX, Dong XP.

Int J Biochem Cell Biol. 2015 May;62:24-35. doi: 10.1016/j.biocel.2015.02.011. Epub 2015 Feb 25.

PMID:
25724737
10.

Calcium- and integrin-binding protein 1 regulates microtubule organization and centrosome segregation through polo like kinase 3 during cell cycle progression.

Naik MU, Naik UP.

Int J Biochem Cell Biol. 2011 Jan;43(1):120-9. doi: 10.1016/j.biocel.2010.10.003. Epub 2010 Oct 15.

11.

MEK1-induced Golgi dynamics during cell cycle progression is partly mediated by Polo-like kinase-3.

Xie S, Wang Q, Ruan Q, Liu T, Jhanwar-Uniyal M, Guan K, Dai W.

Oncogene. 2004 May 6;23(21):3822-9.

PMID:
15021912
12.

Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.

Naik MU, Pham NT, Beebe K, Dai W, Naik UP.

Int J Cancer. 2011 Feb 1;128(3):587-96. doi: 10.1002/ijc.25388.

13.

The Acidophilic Kinases PLK2 and PLK3: Structure, Substrate Targeting and Inhibition.

Cozza G, Salvi M.

Curr Protein Pept Sci. 2018;19(8):728-745. doi: 10.2174/1389203719666180124095405. Review.

PMID:
29366414
14.

Finding Plk3.

Zimmerman WC, Erikson RL.

Cell Cycle. 2007 Jun 1;6(11):1314-8. Epub 2007 Jun 11. Review.

PMID:
17568195
15.

Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects.

Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS.

J Biol Chem. 2007 Jan 26;282(4):2505-11. Epub 2006 Nov 29.

16.

Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis.

Jiang N, Wang X, Jhanwar-Uniyal M, Darzynkiewicz Z, Dai W.

J Biol Chem. 2006 Apr 14;281(15):10577-82. Epub 2006 Feb 14.

17.

Cytoskeletal architecture and cell motility remain unperturbed in mouse embryonic fibroblasts from Plk3 knockout mice.

Michel DR, Mun KS, Ho CC, Stambrook PJ.

Exp Biol Med (Maywood). 2016 Mar;241(6):603-10. doi: 10.1177/1535370216629010. Epub 2016 Feb 2.

18.

The Plk3-Cdc25 circuit.

Myer DL, Bahassi el M, Stambrook PJ.

Oncogene. 2005 Jan 10;24(2):299-305. Review.

PMID:
15640846
19.

Polo-like kinase 3 is Golgi localized and involved in regulating Golgi fragmentation during the cell cycle.

Ruan Q, Wang Q, Xie S, Fang Y, Darzynkiewicz Z, Guan K, Jhanwar-Uniyal M, Dai W.

Exp Cell Res. 2004 Mar 10;294(1):51-9.

PMID:
14980500
20.

[Construction of pMSCV recombinant retroviral vector containing polo-like kinase 3(plk3) cDNA and its effects on cell proliferation].

Jiang S, Feng ZQ, Jiang QL, Li YH, Peng T, Yin H.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 Jan;22(1):29-32. Chinese.

PMID:
16388739

Supplemental Content

Support Center